-
公开(公告)号：US07531172B2
公开(公告)日：2009-05-12
申请号：US11502736
申请日：2006-08-11
CPC分类号： A61K38/179
摘要： A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment of patients unresponsive to treatment with a VEGF inhibitor administered intravenously.
摘要翻译： 在患有可用VEGF拮抗剂治疗的疾病或病症的人类受试者中降低或预防与血管内皮生长因子（VEGF）拮抗剂的给药相关的高血压的方法，其中希望减少或预防高血压。 该方法对于治疗对用静脉内施用的VEGF抑制剂治疗无反应的患者特别有用。
-
2.发明授权Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof 有权含有VEGF抑制剂和5FU或其衍生物的抗肿瘤组合公开(公告)号：US08388963B2
公开(公告)日：2013-03-05
申请号：US12508834
申请日：2009-07-24
申请人： Patricia Vrignaud , Marielle Chiron-Blondel , Marie-Christine Bissery , Eric Furfine , Jocelyn Holash , Jesse M. Cedarbaum
发明人： Patricia Vrignaud , Marielle Chiron-Blondel , Marie-Christine Bissery , Eric Furfine , Jocelyn Holash , Jesse M. Cedarbaum
CPC分类号： A61K31/513 , A61K31/505 , A61K31/519 , A61K31/7068 , A61K38/179 , A61K38/18 , A61K45/00 , A61K2300/00
摘要： This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
摘要翻译： 本发明涉及包含与5-氟尿嘧啶组合的VEGF抑制剂或可用于治疗肿瘤性疾病的5-氟嘧啶衍生物的抗肿瘤组合物，以及包含这些组合的药物组合物。
-
公开(公告)号：US20070037748A1
公开(公告)日：2007-02-15
申请号：US11502736
申请日：2006-08-11
申请人： Neil Stahl , George Yancopoulos , Eric Furfine , Jesse Cedarbaum
发明人： Neil Stahl , George Yancopoulos , Eric Furfine , Jesse Cedarbaum
IPC分类号： A61K38/17
CPC分类号： A61K38/179
摘要： A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment of patients unresponsive to treatment with a VEGF inhibitor administered intravenously.
摘要翻译： 在患有可用VEGF拮抗剂治疗的疾病或病症的人类受试者中降低或预防与血管内皮生长因子（VEGF）拮抗剂的给药相关的高血压的方法，其中希望减少或预防高血压。 该方法对于治疗对用静脉内施用的VEGF抑制剂治疗无反应的患者特别有用。
-
公开(公告)号：US08969289B2
公开(公告)日：2015-03-03
申请号：US13098851
申请日：2011-05-02
申请人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
发明人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
CPC分类号： C12P21/005 , A61K38/00 , A61K47/62 , A61K47/643 , C07K14/435 , C07K14/50 , C07K14/575 , C07K14/78 , C07K2319/70 , C12N15/62
摘要： The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
摘要翻译： 本发明涉及基于结合血清白蛋白的第十纤连蛋白III型结构域（10Fn3）的抗体样蛋白。 本发明还涉及包含与用于诊断和治疗应用的异源蛋白质连接的血清白蛋白结合10Fn3的融合分子。
-
公开(公告)号：US20130012435A1
公开(公告)日：2013-01-10
申请号：US13533382
申请日：2012-06-26
申请人： Ray Camphausen , Eric Furfine , Irvith M. Carvajal , H. Nicholas Marsh , Marco Gottardis , Joan Carboni , Ricardo Attar
发明人： Ray Camphausen , Eric Furfine , Irvith M. Carvajal , H. Nicholas Marsh , Marco Gottardis , Joan Carboni , Ricardo Attar
CPC分类号： C07K14/78 , A61K38/39 , A61K39/3955 , A61K47/60 , A61K2039/505 , C07K14/71 , C07K14/715 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/00 , C07K2319/74
摘要： The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
-
6.发明申请公开(公告)号：US20070293432A1
公开(公告)日：2007-12-20
申请号：US11818463
申请日：2007-06-14
申请人： Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
发明人： Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
IPC分类号： A61K38/17
CPC分类号： C07K14/71 , A61K9/0019 , A61K9/0048 , A61K9/19 , A61K38/179 , A61K38/1793 , A61K47/02 , A61K47/10 , A61K47/26 , A61M5/178 , C07K14/47 , C07K14/4705 , C07K2319/00 , C07K2319/30
摘要： Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
摘要翻译： 提供血管内皮生长因子（VEGF）特异性融合蛋白拮抗剂的眼科制剂适用于玻璃体内给予眼睛。 眼用制剂包括稳定的液体制剂和可冷冻干燥的制剂。 优选地，蛋白质拮抗剂具有SEQ ID NO：4所示的氨基酸序列。
-
公开(公告)号：US08481046B2
公开(公告)日：2013-07-09
申请号：US13329770
申请日：2011-12-19
申请人： Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
发明人： Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
CPC分类号： C07K14/71 , A61K9/0019 , A61K9/0048 , A61K9/19 , A61K38/179 , A61K38/1793 , A61K47/02 , A61K47/10 , A61K47/26 , A61M5/178 , C07K14/47 , C07K14/4705 , C07K2319/00 , C07K2319/30
摘要： Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence of residues 27-457 of SEQ ID NO:4.
摘要翻译： 提供血管内皮生长因子（VEGF）特异性融合蛋白拮抗剂的眼科制剂适用于玻璃体内给予眼睛。 眼用制剂包括稳定的液体制剂和可冷冻干燥的制剂。 优选地，蛋白质拮抗剂具有SEQ ID NO：4的残基27-457的氨基酸序列。
-
8.发明申请公开(公告)号：US20050148548A1
公开(公告)日：2005-07-07
申请号：US10958223
申请日：2004-10-04
申请人： Roger Tung , Michael Hale , Christopher Baker , Eric Furfine , Istvan Kaldor , Wieslaw Kazmierski , Andrew Spaltenstein
发明人： Roger Tung , Michael Hale , Christopher Baker , Eric Furfine , Istvan Kaldor , Wieslaw Kazmierski , Andrew Spaltenstein
IPC分类号： A61K31/18 , A61K31/215 , A61K31/265 , A61K31/27 , A61K31/34 , A61K31/341 , A61K31/4025 , A61K31/496 , A61K31/66 , A61K31/661 , A61K31/664 , A61K31/7048 , A61K45/00 , A61P31/12 , A61P31/18 , A61P43/00 , C07C311/15 , C07C311/18 , C07C311/37 , C07D277/30 , C07D307/20 , C07D405/12 , C07D407/12 , C07D417/12 , C07F9/655 , C07F9/6584 , C07H15/04 , C07H15/26 , A61K31/675 , A61K31/443 , A61K31/4709 , A61K31/551
CPC分类号： C07D405/12 , C07C311/18 , C07D307/20 , C07F9/65515 , C07F9/65844 , C07H15/04
摘要： The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.
摘要翻译： 本发明涉及作为天冬氨酰蛋白酶抑制剂的一类磺酰胺的前药。 在一个实施方案中，本发明涉及HIV天冬氨酰蛋白酶抑制剂的新一类前药，其特征在于有利的水溶性，高口服生物利用度和活性成分的体内易生成。 本发明还涉及包含这些前药的药物组合物。 本发明的前药和药物组合物特别适用于降低药丸负担并增加患者依从性。 本发明还涉及用这些前药和药物组合物治疗哺乳动物的方法。
-
公开(公告)号：US08728483B2
公开(公告)日：2014-05-20
申请号：US13533382
申请日：2012-06-26
申请人： Ray Camphausen , Eric Furfine , Irvith M. Carvajal , H. Nicholas Marsh , Marco Gottardis , Joan Carboni , Ricardo Attar
发明人： Ray Camphausen , Eric Furfine , Irvith M. Carvajal , H. Nicholas Marsh , Marco Gottardis , Joan Carboni , Ricardo Attar
IPC分类号： A61K38/39 , A61K47/48 , C07K14/705 , C07K14/78 , C07K14/435
CPC分类号： C07K14/78 , A61K38/39 , A61K39/3955 , A61K47/60 , A61K2039/505 , C07K14/71 , C07K14/715 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/00 , C07K2319/74
摘要： The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
摘要翻译： 本发明涉及包含通过多肽接头连接的至少两个纤连蛋白支架结构域的多价多肽。 本发明还涉及用于诊断，研究和治疗应用的多价多肽。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
公开(公告)号：US20110305663A1
公开(公告)日：2011-12-15
申请号：US13098851
申请日：2011-05-02
申请人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
发明人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
IPC分类号： A61K38/20 , C07K19/00 , A61K38/17 , A61P3/10 , A61P3/04 , A61K38/18 , A61K38/28 , A61K38/22 , A61K38/26 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/21 , A61P3/00 , A61P3/06 , A61P9/00 , C07K14/47
CPC分类号： C12P21/005 , A61K38/00 , A61K47/62 , A61K47/643 , C07K14/435 , C07K14/50 , C07K14/575 , C07K14/78 , C07K2319/70 , C12N15/62
摘要： The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
摘要翻译： 本发明涉及基于结合血清白蛋白的第十纤连蛋白III型结构域（10Fn3）的抗体样蛋白。 本发明还涉及包含与用于诊断和治疗应用的异源蛋白质连接的血清白蛋白结合10Fn3的融合分子。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.036 秒)
